Specifically, LPS has been associated with reduced efficacy of anti-PD-L1 immunotherapy in CRC, where blocking LPS or its receptor, TLR4, enhances T-cell infiltration into CRC, improves immune responses, and reduces liver metastasis (Song et al., 2018). This evidence concerns the gene TLR4 and colorectal carcinoma.